Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021155323 - COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION-SARS-COV-2 VACCINES

Publication Number WO/2021/155323
Publication Date 05.08.2021
International Application No. PCT/US2021/015946
International Filing Date 30.01.2021
IPC
C07K 14/005 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
CPC
A61K 2039/5256
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
525Virus
5256expressing foreign proteins
A61K 2039/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
53DNA (RNA) vaccination
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61K 2039/55505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55505Inorganic adjuvants
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Applicants
  • BETH ISRAEL DEACONESS MEDICAL CENTER, INC. [US]/[US]
  • JANSSEN PHARMACEUTICALS, INC. [US]/[US]
Inventors
  • BAROUCH, Dan, H.
  • LANGEDIJK, Johannes Petrus, Maria
  • RUTTEN, Lucy
  • BAKKERS, Mark Johannes, Gerandus
  • BOS, Rinke
  • WEGMANN, Frank
  • ZUIJDGEEST, David Adrianus Theodorus, Maria
  • VANDEBOSCH, An
  • LE GARS, Mathieu Claude, Michel
  • SADOFF, Jerald, C.
Agents
  • BARANIAK, Andrew, P.
  • BOSE, Siddharth
  • BANTA, Holiday, W.
  • COLE, Troy, J.
  • BERG, Amy
Priority Data
310113128.11.2020CA
62/705,18715.06.2020US
62/705,30821.06.2020US
62/706,36612.08.2020US
62/706,67602.09.2020US
62/706,93718.09.2020US
62/706,95821.09.2020US
62/969,00831.01.2020US
62/994,63025.03.2020US
63/014,46723.04.2020US
63/025,78215.05.2020US
63/043,09023.06.2020US
63/066,14714.08.2020US
63/112,90012.11.2020US
63/121,48204.12.2020US
63/133,96905.01.2021US
63/135,18208.01.2021US
63/141,91326.01.2021US
63/142,97728.01.2021US
63/198,08928.09.2020US
63/198,30609.10.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION-SARS-COV-2 VACCINES
(FR) COMPOSITIONS ET PROCÉDÉS DE PRÉVENTION ET DE TRAITEMENT D'UNE INFECTION PAR LE CORONAVIRUS - VACCINS CONTRE LE SARS-COV-2
Abstract
(EN) The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019- nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.
(FR) L'invention concerne des compositions immunogènes et des vaccins contenant une protéine du coronavirus (par exemple, le coronavirus Wuhan (2019-nCoV; également appelé SARS-CoV -2)) ou un polynucléotide codant pour une protéine du coronavirus (par exemple, le coronavirus Wuhan (2019-nCoV; SARS-CoV -2)) et leurs utilisations. L'invention concerne également des procédés de traitement et/ou de prévention d'une infection par le coronavirus (par exemple, le coronavirus Wuhan (2019-nCoV; SARS-CoV -2)) par administration d'une composition immunogène ou d'un vaccin à un sujet (par exemple, un être humain). L'invention concerne également des procédés de détection et/ou de surveillance d'une réponse protectrice des anticorps contre le coronavirus (par exemple, le coronavirus Wuhan (2019-nCoV; le SARS-CoV -2)) (par exemple, une réponse des anticorps contre le coronavirus, par exemple, une réponse des anticorps contre le 2019-nCoV, par exemple, une réponse des anticorps anti-spicule, par exemple, une réponse des anticorps neutralisants anti-spicule). La présente invention concerne un acide nucléique isolé et/ou recombinant codant pour une protéine S du coronavirus, en particulier une protéine S du SARS-CoV -2, et les protéines S du coronavirus, ainsi que l'utilisation des acides nucléiques et/ou de leurs protéines dans des vaccins.
Latest bibliographic data on file with the International Bureau